Enzyme replacement therapy in porphyrias--IV. First successful human clinical trial of delta-aminolevulinate dehydratase-loaded erythrocyte ghosts.
A patient with chronic lead intoxication was treated with only one course of highly purified human blood aminolaevulinate dehydratase entrapped in autologous erythrocyte ghosts given intravenously. No untoward effects were observed during or after infusion. An immediate increase in the patient's erythrocyte dehydratase activity was detected 1 hr after enzyme administration, reaching its maximum and nearly normal level 2 days later, values remained unchanged for a week, to slowly diminish after 2 weeks of initiated the treatment, and finally recovered activity was kept practically leveled off for weeks. This novel therapeutic trial produced complete improvement both clinical and biochemical, showing that enzyme infusion has been beneficial and can be safely and successfully used in the treatment of human lead intoxication.
D000328:Adult; D003306:Coproporphyrins / Q000378:metabolism; D004910:Erythrocyte Membrane; D006801:Humans; D007275:Injections, Intravenous; D007855:Lead Poisoning / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D000623:Porphobilinogen Synthase / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D011166:Porphyrins / Q000378:metabolism*; D014578:Uroporphyrins / Q000378:metabolism
D003306:Coproporphyrins; D011166:Porphyrins; D014578:Uroporphyrins; D000623:Porphobilinogen Synthase